MA29561B1 - DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE - Google Patents

DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE

Info

Publication number
MA29561B1
MA29561B1 MA30502A MA30502A MA29561B1 MA 29561 B1 MA29561 B1 MA 29561B1 MA 30502 A MA30502 A MA 30502A MA 30502 A MA30502 A MA 30502A MA 29561 B1 MA29561 B1 MA 29561B1
Authority
MA
Morocco
Prior art keywords
pyrido
preparation
pyrimidine derivatives
therapeutic application
compounds
Prior art date
Application number
MA30502A
Other languages
English (en)
French (fr)
Inventor
Bernard Bourrie
Pierre Casellas
Samir Jegham
Claude Muneaux
Pierre Perreaut
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29561B1 publication Critical patent/MA29561B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA30502A 2005-07-01 2007-12-24 DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE MA29561B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507032A FR2887882B1 (fr) 2005-07-01 2005-07-01 Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique

Publications (1)

Publication Number Publication Date
MA29561B1 true MA29561B1 (fr) 2008-06-02

Family

ID=36096420

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30502A MA29561B1 (fr) 2005-07-01 2007-12-24 DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE

Country Status (40)

Country Link
US (2) US7504406B2 (enExample)
EP (2) EP1902054B1 (enExample)
JP (1) JP4472009B2 (enExample)
KR (1) KR101298344B1 (enExample)
CN (2) CN101213196B (enExample)
AR (1) AR054812A1 (enExample)
AT (1) ATE423119T1 (enExample)
AU (1) AU2006264801B2 (enExample)
BR (1) BRPI0613020A2 (enExample)
CA (1) CA2610794C (enExample)
CR (1) CR9568A (enExample)
CY (2) CY1110457T1 (enExample)
DE (1) DE602006005246D1 (enExample)
DK (2) DK2020410T3 (enExample)
DO (1) DOP2006000145A (enExample)
EA (1) EA014312B1 (enExample)
EC (1) ECSP078011A (enExample)
ES (2) ES2450067T3 (enExample)
FR (1) FR2887882B1 (enExample)
HR (2) HRP20090236T1 (enExample)
IL (1) IL187900A0 (enExample)
JO (1) JO2550B1 (enExample)
MA (1) MA29561B1 (enExample)
ME (1) ME01813B (enExample)
MX (1) MX2007016239A (enExample)
MY (1) MY143089A (enExample)
NO (1) NO20080418L (enExample)
NZ (1) NZ564072A (enExample)
PA (1) PA8684801A1 (enExample)
PE (1) PE20070139A1 (enExample)
PL (2) PL2020410T3 (enExample)
PT (2) PT1902054E (enExample)
RS (2) RS53211B (enExample)
SI (2) SI2020410T1 (enExample)
TN (1) TNSN07440A1 (enExample)
TW (1) TWI321566B (enExample)
UA (1) UA92021C2 (enExample)
UY (1) UY29645A1 (enExample)
WO (1) WO2007003765A1 (enExample)
ZA (1) ZA200711032B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AU2009304596A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1P receptors modulators
JP2012505836A (ja) 2008-10-17 2012-03-08 アカール ファーマ ピーティーワイ リミテッド Ｓ１ｐ受容体モジュレーターおよびそれらの使用
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
CN103204822B (zh) * 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
EP2638911A1 (en) 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
CN103833771A (zh) * 2012-11-22 2014-06-04 天津滨江药物研发有限公司 作为蛋白激酶Mek抑制剂的苯并五元杂环化合物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
JPH04128276A (ja) 1990-09-19 1992-04-28 Pfizer Pharmaceut Co Ltd アミノベンゾサルタム誘導体およびその用途
MX9702245A (es) * 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2001055147A1 (en) * 2000-01-25 2001-08-02 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
EE200200506A (et) * 2000-03-06 2004-02-16 Warner-Lambert Company 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
JP2004519422A (ja) 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections

Also Published As

Publication number Publication date
UA92021C2 (ru) 2010-09-27
SI1902054T1 (sl) 2009-06-30
JP4472009B2 (ja) 2010-06-02
JP2008544975A (ja) 2008-12-11
TWI321566B (en) 2010-03-11
KR101298344B1 (ko) 2013-08-20
DOP2006000145A (es) 2008-01-31
ECSP078011A (es) 2008-01-23
DK1902054T3 (da) 2009-06-15
RS53211B (sr) 2014-08-29
ATE423119T1 (de) 2009-03-15
NO20080418L (no) 2008-03-28
SI2020410T1 (sl) 2014-04-30
PE20070139A1 (es) 2007-03-07
PL2020410T3 (pl) 2014-05-30
MY143089A (en) 2011-03-15
HK1122797A1 (en) 2009-05-29
ME01813B (me) 2014-09-20
JO2550B1 (en) 2010-09-05
EP1902054B1 (fr) 2009-02-18
KR20080021714A (ko) 2008-03-07
PL1902054T3 (pl) 2009-07-31
AU2006264801A1 (en) 2007-01-11
ZA200711032B (en) 2009-04-29
CN101213196B (zh) 2011-09-07
WO2007003765A1 (fr) 2007-01-11
PA8684801A1 (es) 2007-01-17
CR9568A (es) 2008-02-20
CA2610794A1 (fr) 2007-01-11
TW200745102A (en) 2007-12-16
FR2887882A1 (fr) 2007-01-05
RS50781B (sr) 2010-08-31
HRP20090236T1 (hr) 2009-05-31
MX2007016239A (es) 2008-03-06
CY1114989T1 (el) 2016-12-14
US20080176874A1 (en) 2008-07-24
PT1902054E (pt) 2009-04-22
EA200800223A1 (ru) 2008-06-30
NZ564072A (en) 2012-02-24
EA014312B1 (ru) 2010-10-29
EP2020410B1 (fr) 2013-12-18
BRPI0613020A2 (pt) 2010-12-14
PT2020410E (pt) 2014-03-20
DE602006005246D1 (de) 2009-04-02
CA2610794C (fr) 2012-02-21
ES2450067T3 (es) 2014-03-21
AU2006264801B2 (en) 2012-05-10
CY1110457T1 (el) 2015-04-29
US8008310B2 (en) 2011-08-30
DK2020410T3 (en) 2014-03-24
IL187900A0 (en) 2008-03-20
FR2887882B1 (fr) 2007-09-07
US7504406B2 (en) 2009-03-17
ES2322101T3 (es) 2009-06-16
EP2020410A1 (fr) 2009-02-04
UY29645A1 (es) 2007-01-31
CN102260258A (zh) 2011-11-30
US20090163522A1 (en) 2009-06-25
AR054812A1 (es) 2007-07-18
CN101213196A (zh) 2008-07-02
HRP20140246T1 (hr) 2014-06-20
TNSN07440A1 (en) 2009-03-17
CN102260258B (zh) 2015-01-07
EP1902054A1 (fr) 2008-03-26

Similar Documents

Publication Publication Date Title
TNSN04126A1 (fr) 2-(pyridine-2-ylamino)-pyrido[2,3d] pyrimidine-7-ones
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
MY138352A (en) Benzothiazole derivatives
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
MXPA03004832A (es) Compuestos y sus usos.
GEP20104962B (en) Fused heterocyclic compounds
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
DE60230683D1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200514781A (en) Novel compounds
MA29643B1 (fr) Benzocycloheptapyridines comme inhibiteurs du recepteur tyrozine kinase met
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
PT1673354E (pt) Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.